- $29.21bn
- $27.90bn
- $1.62bn
2019 July 31st | 2020 July 31st | 2021 July 31st | 2022 July 31st | 2023 July 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 303 | 431 | 673 | 1,091 | 1,617 |
Cost of Revenue | |||||
Gross Profit | 243 | 336 | 523 | 849 | 1,254 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 338 | 545 | 881 | 1,418 | 1,852 |
Operating Profit | -35.3 | -114 | -208 | -327 | -235 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -27.9 | -113 | -257 | -384 | -183 |
Provision for Income Taxes | |||||
Net Income After Taxes | -28.7 | -115 | -262 | -390 | -202 |
Net Income Before Extraordinary Items | |||||
Net Income | -28.7 | -115 | -262 | -390 | -202 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -28.7 | -115 | -262 | -390 | -202 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.163 | -0.794 | -1.93 | -2.77 | -1.36 |